Clinical Trials
3 trialsNCT02487979 2022-01-18
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02363283 2020-08-21
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02713828 2019-07-16
PrE0504
PrECOG, LLC.
Phase 1/2 Terminated